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Dr. Samuel Silverman, 62, is one psychoanalyst willing to declare that
Richard Nixon’s phlebitis is psychosomatic. The man has been under
extraordinary pressure for more than a year, Dr. Silverman says. Mr. Nixon
seems to keep his emotions under such control that we might have expected
physical instead of emotional breakdown.
Time Magazine, September 30, 1974, p. 65.
This introductory “case vignette” raises the question of
whether intense emotional stress, such as experienced by
the United States President Nixon in the wake of the
Watergate scandal, is capable of causing thrombosis-
associated diseases and, if so, by which mechanisms.
Thus, the aim of this review is to provide an update on
the sizeable literature on stress-related changes in the
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Abstract Numerous naturalistic, experimental, and mechanistic studies strongly support the notion
that—as part of ﬁght-or-ﬂight response—hemostatic responses to acute psychosocial stress
result in net hypercoagulability, whichwould protect a healthy organism frombleeding in case
of injury. Sociodemographic factors, mental states, and comorbidities are important modu-
lators of the acute prothrombotic stress response. In patients with atherosclerosis, exaggerat-
ed and prolonged stress-hypercoagulability might accelerate coronary thrombus growth
following plaque rupture. Against a background risk from acquired prothrombotic conditions
and inherited thrombophilia, acute stress also might trigger venous thromboembolic events.
Chronic stressors such as job strain, dementia caregiving, and posttraumatic stress disorder as
well as psychological distress fromdepressive and anxiety symptoms elicit a chronic low-grade
hypercoagulable state that is no longer viewed as physiological but might impair vascular
health. Through activation of the sympathetic nervous system, higher order cognitive
processes and corticolimbic brain areas shape the acute prothrombotic stress response.
Hypothalamic–pituitary–adrenal axis and autonomic dysfunction, including vagal withdrawal,
are important regulators of hemostatic activity with longer lasting stress. Randomized
placebo-controlled trials suggest that several cardiovascular drugs attenuate the acute
prothrombotic stress response. Behavioral interventions and psychotropic medications might
mitigate chronic low-grade hypercoagulability in stressed individuals, but further studies are
clearly needed. Restoring normal hemostatic function with biobehavioral interventions bears
the potential to ultimately decrease the risk of thrombotic diseases.
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hemostatic system (i.e., coagulation, ﬁbrinolysis, and platelets)
and their potential role in thrombosis. As a prerequisite for
the notion that stress-associated hypercoagulability con-
tributes to thrombotic events,1 abundant epidemiological
and experimental data exist supporting the role of enhanced
coagulation, impaired ﬁbrinolysis, and hyperactive platelets
in the development of atherogenesis, atherothrombosis, and
acute coronary syndromes (ACSs).2 Also, against a back-
ground risk from acquired prothrombotic conditions (e.g.,
varicosis, immobility) and inherited thrombophilia, even
“trivial” triggers such as stress, might bring forward a
prothrombotic state that results in onset of venous throm-
boembolism (VTE).3
After introducing the evolutionary meaning versus
potential harm for the vasculature of a prothrombotic
stress response, we present epidemiological and observa-
tional data on the role of stress in atherothrombotic
diseases and VTE. We then depict the most salient mech-
anisms that may link psychosocial stress with hemostatic
alterations, including the role of the brain and important
health characteristics. Finally, we summarize ﬁndings
from randomized, placebo-controlled drug trials, and be-
havioral interventions targeting stress-related hemostatic
changes.
Evolutionary Beneﬁt versus Health Risk
First, we should highlight an important distinction between
thevascular consequences of acute versus chronic stress effects
onhemostasis. In the case of acute stress, a prothrombotic state
is clearly viewed as an adaptive physiological response to
prevent a healthy organism in ﬁght-or-ﬂight situations from
potentially excessive bleeding in case of injury.4 However, due
to a dysfunctional endothelium having lost its anticoagulant
properties (e.g., reduced release of nitric oxide and tissue-type
plasminogen activator [t-PA]),5 the prothrombotic stress
response may be excessive in patients with cardiovascular
disease (CVD), which may increase the risk of stress-triggered
atherothrombotic events.1 For instance, if tested 1 year after
having survived an ACS, patients who reported emotional
triggering showed signiﬁcantly greater increases and longer
recovery of platelet-leukocyte aggregates after acute psycho-
social stress than the nontriggering group.6 In the case of
chronic stress, sustained low-grade hypercoagulability does
not seem to be of evolutionary beneﬁt in healthy individuals
and might be harmful to the cardiovascular system in the long
run, contributing to atherosclerosis progression.4,5,7 Such
harm might pose greater risk in those with comorbid con-
ditions and thrombotic risk factors. Therefore, individualswith
the largest prothrombotic responses to stress and the greatest
stress exposure in everyday life would be predicted to be at
greater risk for thrombotic diseases.8
Stress and Thrombotic Disorders
Meta-analyses from the past decade strongly suggest that psy-
chosocial stress contributes to morbidity and mortality from
atherothrombotic CVD with a 1.5- to 2.5-fold excess risk.8,9
In the worldwide INTERHEART case–control study, one-third
of the population attributable risk ofmyocardial infarction (MI)
could be assigned to psychosocial factors, including major life
events, lack of control, depression, work stress, family stress,
and ﬁnancial stress.10 The effect size of MI risk explained by
psychosocial stress in INTERHEART was similar to that ex-
plained by traditional CVD risk factors.
Similarly, evidence from prospective studies suggests
that psychosocial factors are predictive of VTE. Persistently
perceived stress and low socioeconomic status (SES)
increase the risk of VTE independent of demographics,
lifestyle, and CVD risk factors.11,12 Depressed subjects
from a population-based study had a 1.6-fold higher risk
of incident VTE over a median follow-up of 12 years com-
pared with those not depressed, controlling for other risk
factors.13 Conversely, those who often felt happy or opti-
mistic had a reduced risk of VTE.13 Acute traumatic stress
arising after natural disasters has been implicated as a
potential triggering factor of pulmonary embolism.14
Moreover, the mental stress from fear of ﬂying with the
accompanying coagulation activation may contribute to
VTE during long-haul air travel.15
Several mechanisms are suggested to link stress to
increased risk of atherothrombotic events6,7 and similar
factors may play a role in VTE.16 Stress particularly promotes
adverse health behaviors and initiates autonomic and neuro-
endocrine changes, all bringing forth physiological perturba-
tions (e.g., hypercoagulability) which are potentially harmful
to the vasculature.1,4,5,7,17–19 We will now discuss mecha-
nisms possibly contributing to acute and chronic hemostatic
changes as part of the human stress response, including brain
processing of stressful stimuli and autonomic and neuroen-
docrine functioning.
Psychosocial Stress, the Brain, and the
Prothrombotic State
“Stress” is an ambiguous term embedding different processes,
namely, a stimulus (i.e., the “stressor” in the form of environ-
mental challenges), perceptual processing of this input (i.e.,
perceived “distress”with the accompanying negative effects),
and behavioral and physiological output (i.e., the “stress
response”).20 This cascade of events helps explain why not
only demanding life circumstances (e.g., providing care to a
spouse with dementia, working overtime), but also perceived
distress (e.g., depressive symptoms) arising from such life
circumstances have emerged as risk factors of CVD.7 ►Fig. 1
shows a conceptual model of how stress may be linked to
prothrombotic states and thrombosis.
Importantly, the stress response (e.g., the magnitude of an
increase in clotting factor activity) is not a direct indicator of
stress exposure, but needs to consider higher level of cortical
information processing, such as cognitive appraisal.20 The
amount of threat and challenge a person appraises depends
upon the predictability of the stressor and perceived coping
resources (e.g., controllability of the situation), which will
ultimately inﬂuence the intensity and duration of the stress
response.21 For example, healthy men who reported greater
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stress appraisal had greater increase and longer recovery of
D-dimer levels over a 1-hour period following the Trier Social
Stress Test (TSST), which combines amock job interviewwith
mental arithmetic in front of an audience for a total of 15
minutes.22
A role of the brain in shaping the procoagulant stress
response is further evidenced by imaging studies showing
corticolimbic brain areas to be jointly involved in processing
stressors and regulating hemodynamic stress responses per-
tinent to CVD risk.23 Congruent with these neuroimaging
studies, early studies demonstrated that electrical stimula-
tion of the lateral hypothalamus in dogs resulted in elevated
clotting factor VIII activity (FVIII:C), whereas decreased FVIII:C
was observed if the hippocampus was stimulated, with effects
lasting approximately 1 hour.24 Moreover, brain serotonergic
neurotransmission dysfunction is evident in stress-related
mental disorders such as depression and anxiety. Platelets of
depressed and anxious individuals showheightened responses
to serotonin.25,26 Moreover, the 5-HT2A receptors in platelets
and brain neurons share similarities with the same gene
encoding for the platelet and brain serotonin transporter.27
A brain-platelet-coronary artery interface was proposed,
whereby serotonergic dysfunction related to stress might
increase the risk of coronary thrombosis through platelet
activation.28
Acute Stress and Hemostasis
Studies in Healthy Individuals
Numerous studies have investigated changes in hemostasis
factors in response to acute psychosocial stressors applied in
naturalistic and laboratory settings (►Table 1), the latter
using standardized speech tasks, mental arithmetic, mirror
star tracing task, and the Stroop color-word conﬂict test. In
healthy individuals, there is an increase in procoagulant
markers, namely, FVII:C, FVIII:C, FXII:C, ﬁbrinogen, platelets,
and von Willebrand factor antigen (VWF:Ag), and of proﬁ-
brinolytic t-PA indicating, on the whole, concomitant activa-
tion of coagulation and ﬁbrinolysis pathways with acute
psychosocial stress.1,4,5,7,18,19 Levels of the coagulation acti-
vation markers thrombin–antithrombin complex (TAT) and
D-dimer increase as well.22,29 Thus, both coagulation and
ﬁbrinolysis increase during acute stress, but coagulation
increases more than ﬁbrinolysis, resulting in net hypercoag-
ulability. Activity of several clotting factors (FVII:C, FVIII:C,
FXII:C) as well as ﬁbrinogen and VWF:Ag levels increased
between 5 and 10% in response to acute stress in healthy
subjects; this change was reproducible across three testings
with 1-week intervals.30 Accordingly, percent prothrombin
time (PT%) signiﬁcantly increased (i.e., indicating activation of
the extrinsic coagulation pathway) and activated partial
Fig. 1 Processes in the relationship between stress, hemostasis, and thrombosis. Depending on cortical information processing and appraised
coping resources, environmental challenges initiate autonomic- and neuroendocrine-driven changes in the hemostatic system. Several
demographic and health-related factors modulate and acquired prothrombotic conditions enhance the prothrombotic stress response, whichmay
become pathological if excessive or chronic, thereby increasing thrombosis risk. Coag, coagulation activation; FL, ﬁbrinolysis activation; HPA,
hypothalamic–pituitary–adrenal axis; SNS, sympathetic nervous system (" ¼ increased, # ¼ decreased).
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thromboplastin time (aPTT) signiﬁcantly decreased (i.e.,
indicating activation of the intrinsic coagulation pathway)
during the TSST in healthy men between 20 and 50 years of
age.31 In agreement with the ﬁght-or-ﬂight response that
protects organisms for a limited time, coagulation and plate-
let activity return to prestress levels within 20 to 45 minutes
after termination of a laboratory stressor.30,32,33
Modulating Factors of the Acute Prothrombotic Stress
Response
Several sociodemographic, health-related, psychosocial, and
behavioral factors are associated with excessive and pro-
longed hypercoagulability and thus might adversely impact
vascular health (►Fig. 1). Age was positively associated with
an increase in D-dimer levels during stress and 20 minutes
poststress,33 suggesting that the risk for stress-triggered
thrombosis may be increased in elderly people. Men experi-
enced greater net stress-hypercoagulability than women,
indexed by a greater FVII:C increase to acute stress in men
and greater t-PA activity in women.34,35 Among those of low
SES the stress-induced increase in FVIII:C remained elevated
45 minutes poststress, whereas FVIII:C returned to baseline
levels among intermediate- and high-SES individuals.36
Compared with individuals free of CVD, those with coro-
nary heart disease (CHD) and/or systemic hypertension
showed greater platelet activation,32,37 delayed recovery of
platelet activity,32 greater D-dimer increase,38 delayed recov-
ery ofdeclined (i.e., consumed) antithrombin III,39 and reduced
ﬁbrinolysis activation,40 all in response to acute stress.
Chronic stress and negative effects were also shown to
exaggerate the acute prothrombotic stress response. For in-
stance, men with higher job stress showed greater VWF:Ag
response to acute stress.41 In caregivers of a spouse with
dementia, the number of negative life events during the last
month correlated directly with changes in a prothrombotic
score comprising procoagulant factors (i.e., TAT, D-dimer,
VWF:Ag, t-PA:Ag) and antiﬁbrinolytic plasminogen activator
inhibitor (PAI)-1:Ag during speech stress.42 In caregivers, but
not in controls, depressive and anxiety symptoms were also
related to increased expression and delayed recovery of plate-
let P-selectin with acute stress, controlling for age, sex, history
of CHD, and use of aspirin and antidepressants.43
Factors associated with good cardiovascular health (e.g.,
positive effects and a diet rich in catechins) may favorably
affect (i.e., mitigate) the prothrombotic stress response.
Greater happiness over a working day was associated with
lower ﬁbrinogen responses to color-word interference and
mirror tracing tasks after adjustment for sociodemographic
and CVD risk factors.44 Finally, platelet activation during
acute stress was reduced after 6 weeks of black tea intake
(i.e., increased catechin consumption) relative to placebo
treatment.45
Underlying Physiological Mechanisms with Acute
Stress
The sympathetic nervous system (SNS) exerts major effects
on hemostasis at times of acute stress.46 A previous system-
atic review of human studies examined hemostatic changes
after infusions of adrenergic compounds with and without
administration of adrenergic blockers.47 Catecholamines,
particularly epinephrine, stimulate vascular endothelial β2-
adrenergic receptors within a few minutes and in a dose-
dependent fashion, resulting in release of preformed FVIII,
VWF, and t-PA from endothelial storage pools into the circu-
lation.47 Catecholamines also stimulate hepatic release of
FVIII and affect hepatic clearance of t-PA and likely of D-
dimer. Sympathetic nerves in densely innervated resistance
arteries and arterioles are another important source of acute
stress-induced release of t-PA into the circulation.48 More-
over, greater sensitivity of the β2-adrenergic receptor and
norepinephrine increasewere both associatedwith increased
TAT levels during acute stress,29 and there was a direct
relationship between stress-induced increases in norepi-
nephrine and D-dimer.22 Stress-induced change in D-dimer
was signiﬁcantly associated with change in FVII:C, explaining
43% of themutual variance, but not with change in ﬁbrinogen,
FVIII:C, FXII:C, VWF:Ag, or soluble tissue factor (sTF).49 Con-
sistent with SNS overactivity observed in hypertensive indi-
viduals, infusion of the nonselective β-receptor agonist
isoproterenol resulted in greater increase of plasma VWF in
hypertensives than in normotensives.50
Thrombin is a potent platelet agonist, and if formed during
stress, might critically contribute to platelet activation in
vivo.29 During acute stress, platelets are activated by stimu-
lation of their α2-adrenergic receptors, whereby stimulation
Table 1 Reliable changes in hemostasis factors with stress
observed in several studies
Measure Acute
stress
Chronic
stress
Fibrinogen " "
Factor XII:C " ?
Factor VII:C " "
Factor VIII:C " "
von Willebrand factor antigen " "
Platelet activity " "
Thrombin–antithrombin complex " ?
Fibrin D-dimer " "
Percent prothrombin time " ?
Activated partial
thromboplastin time
# —
Tissue-type plasminogen
activator activity
" #
Tissue-type plasminogen
activator antigen
? "
Plasminogen activator
inhibitor-1 (antigen and activity)
— "
Notes: Qualitative changes (", increased level; #, decreased level; —, no
change; ?, unclear). While there is coagulation and platelet activation in
both acute and chronic stress conditions, ﬁbrinolysis is activated with
acute stress but attenuated with chronic stress.
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of their β2-adrenergic receptors seems to exert platelet inhibi-
tion.47 Compared with normotensives, patients with essential
hypertension showed greater platelet activation (i.e., greater
platelet size, increased plasma β-thromboglobulin [βTG]
levels) to a physiological dose of infused epinephrine.51
In addition to SNS-related mechanisms governing acute
hemostatic stress responses, plasma volume contraction (i.e.,
hemoconcentration) also inﬂuences hemostatic measures
during acute stress. In healthy individuals, this stress-hemo-
concentration is facilitated by an acute increase in blood
pressure and net efﬂux of plasma into the interstitial spaces,
thereby resulting in an elevated intravascular concentration
of nondiffusible blood constituents (i.e., greater than 69 kDa),
including ﬁbrinogen, prothrombin, FV, FVIII, FXI, FXII, and the
VWF.7 The mechanisms underlying stress-hemoconcentra-
tion in patients with CHD are less clear.52 Acute stress-
induced changes in plasma volume only explain between 4
and 10% of the variance in changes of FVII:C, FVIII:C, and FXII:
C.49 The most accurate methods to investigate the relative
contribution of stress-hemoconcentration to the acute pro-
thrombotic stress response are of current debate.53–55 Arith-
metic adjustment for stress-hemoconcentration has differing
effects on ﬁbrinogen, FVII:C, FVIII:C, FXII:C, VWF:Ag, PT%, and
aPTT.31,56 Saline reconstitution of contracted plasma sug-
gested that stress-induced elevations of most measures was
due to hemoconcentration, with the notable exception of
FVIII:C.31 In fact, no correction technique removed the effects
for FVIII:C, suggesting that the intrinsic pathway is genuinely
activated during acute stress.31,56
Other psychobiological processes contributing to emo-
tional triggering of ACS include stress-induced hemodynamic
shear forces to a vulnerable plaque and inﬂammatory re-
sponses involving cytokines further destabilizing plaques.57
Moreover, the hemostatic and inﬂammatory systems are
associated during stress. After the TSST, D-dimer and inter-
leukin (IL)-6 reactivity showed a signiﬁcant and positive
correlation over a 2-hour period.58
Chronic Stress and Hemostasis
Different domains of chronic psychosocial stress and distress
(e.g., SES, job stress, caregiver stress, posttraumatic stress
disorder [PTSD]) have been associated with hemostatic alter-
ations. Similar to acute stress, procoagulant markers, partic-
ularly ﬁbrinogen, D-dimer, FVII:C, FVIII:C, and VWF:Ag, are
increased by chronic stress (►Table 1).4,5,19 Importantly,
opposed to acute stress, chronic stress seems to impair
ﬁbrinolytic activity, reﬂected by increased PAI-1:Ag, PAI-1
activity, and t-PA:Ag, but decreased t-PA activity. Thus,
chronic stress shifts the hemostatic balance between coagu-
lation and ﬁbrinolysis toward a chronic low-grade hyperco-
agulable state potentially increasing risk of thrombotic
disease.4,5,19
Low Socioeconomic Status
Low SES can be construed as a state of chronic stress.59 Substan-
tial evidence supports a relationship between low SES as
measured by different constructs (e.g., education, occupational
class, and social class) and elevated levels of ﬁbrinogen, FVII:C,
and VWF:Ag.4 A large meta-analysis revealed higher ﬁbrinogen
levels in unemployed persons than in employedworkers, aswell
as in individualswith lower versus higher education, controlling
for a range of CVD risk factors.60
Job Stress
Stress at work—deﬁned as a mismatch between job demands
and decision latitude (i.e., high job strain)61 or as an imbalance
between effort spent and reward obtained62—has been asso-
ciated with elevated ﬁbrinogen and FVII:C and reduced ﬁbri-
nolytic capacity (i.e., decreased t-PA activity and increased PAI-
1:Ag), mainly in cross-sectional studies.4 Accountants showed
increased FVII:C, FVIII:C, and ﬁbrinogen aswell as exaggerated
adenosine diphosphate (ADP)- and thrombin-induced platelet
aggregation, but no difference in PT and aPTT, during a period
of increased work load relative to a calmer period.63 In male
Korean workers with high job strain, FVIII:C, but not FVII:C,
was increased after controlling for smoking, blood pressure,
and lipids.64 A recent review suggests that the relation be-
tween an adverse psychosocial working environment and
elevated ﬁbrinogen is a robust one.65
Caregiver Stress
Providing in-home informal care to a demented spouse is a
natural model of chronic human stress. We found higher
resting D-dimer levels in Alzheimer caregivers than in age-
and sex-matched noncaregiving controls, controlling for his-
tory of CHD, CVD risk factors, lifestyle, and medications.66
Elevated D-dimer levels among caregivers were directly
associated with norepinephrine and perturbed sleep mea-
sured by polysomnography.67,68 Problem behaviors of the
spouse with dementia were associated with a procoagulant
index that included VWF:Ag, PAI-1:Ag, and D-dimer in the
caregiver.69 After the care recipient was deceased or placed in
a long-term care facility, D-dimer levels in caregivers did not
return to levels of noncaregiving controls until 6 to 30months
after the transition.70
Posttraumatic Stress Disorder
Typically, patients with PTSD reexperience aspects of a trau-
matic event, such as combat, accidents, and MI in thoughts or
dreams, and avoid cues/activities reminding them of the event
and develop hyperarousal symptoms, such as irritability and
insomnia, all during at least 1 month. Following an accident,
patients with PTSD had signiﬁcantly higher levels of sTF than
those who did not develop PTSD.71 Reexperiencing and avoid-
ance symptoms as well as total PTSD symptoms also showed
direct associations with sTF,71 while hyperarousal and total
PTSD symptoms were directly associated with plasma ﬁbrino-
gen levels.72 Among civilians with war-related chronic PTSD,
VWF:Ag levels were signiﬁcantly higher than in non-PTSD
controls; additionally, the most severe PTSD cases had higher
VWF:Ag and FVIII:C than those with less severe PTSD symp-
toms and controls.73 Conversely, PTSD symptomatology was
unrelated to baseline levels of PT, aPTT, FVII:C, D-dimer,
ﬁbrinopeptide A, and prothrombin fragments 1 þ 2 across
several studies.72–74 Baseline platelet activity and soluble
Seminars in Thrombosis & Hemostasis Vol. 39 No. 8/2013
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P-selectin did not differ between combat veterans with and
without PTSD75; however, platelets from PTSD patients
showed exaggerated reactivity to in vitro epinephrine/ADP
stimulationmediated by theα2-adrenergic receptor.76 Post-MI
patients with PTSD caused by their MI showed a signiﬁcant
increase in soluble P-selectin during a trauma interview
compared with non-PTSD controls77 and increased ﬁbrinogen
and D-dimer reactivity if perceived stress before the interview
was high.74
Psychological Distress
Psychological distress can be conceptualized as amaladaptive
behavioral response in the form of negative effects, such as
depressive and anxiety symptoms both of which may reach a
degree that qualiﬁes for a clinical/psychiatric diagnosis (e.g.,
major depression, panic disorder).9 Depression has been
associated with an increased platelet activity78 and elevated
ﬁbrinogen levels19 in numerous studies. Patients with ACS
and clinical depression showed higher plasma levels of
platelet releasing factors (platelet factor 4, βTG) compared
with ACS patientswithout clinical depression.79 Two prospec-
tive studies showed direct correlations between depressive
symptom scores and ﬁbrinogen levels across ﬁve annual
assessments in women80 and across two annual assessments
in teachers.81 Higher self-rated distress was associated with
greater ﬁbrinogen levels in a large sample of healthy young
adults, controlling for a range of important confounders.82
Plasma levels of PAI-1 activity were also greater in depressed
than nondepressed individuals, independent of traditional
CVD risk factors and status of CHD.83
In patients with previous VTE referred for diagnostic
thrombophilia work up, we showed a direct association of
depressive symptoms with TAT levels and, in those with low
perceived social support, also with D-dimer levels, after con-
trolling for demographic and medical covariates.84 In VTE
patients, more symptoms of depression, anxiety, worrying,
and anger were all associated with a reduced international
normalized ratio, suggesting hastened clotting of the extrinsic
coagulation pathway; worrying anger and hostility also
showed a direct association with FVII:C levels.85 Interestingly,
relatively lower FX:C in relation to anxiety and worrying and
relatively lower FVII:C in relation to anger and hostility were
observed in patients with oral anticoagulant (OAC) therapy
compared with those without.85 This difference might be
explained by a stress-related innate immune response86 that
attenuates the metabolism of OACs to increase inhibition of
vitamin K-dependent clotting factors.87
Predominantly impaired ﬁbrinolysis (i.e., increased PAI-1:
Ag andα2-antiplasmin levels) has been found in patientswith
an anxiety disorder.88 Moreover, similar to healthy controls,
those anxiety patients medicated with a serotonergic antide-
pressant showed lower ﬁbrinogen and PAI-1:Ag levels and
higher plasmin-α2-antiplasmin complex, relative to patients
with no serotonergic antidepressant.89 Anxiety symptoms
were associated with increased platelet reactivity to seroto-
nin using ﬂow cytometry in CHD patients.25 In factory work-
ers, panic-like anxiety was associated with higher D-dimer
and lower ﬁbrinogen levels, but not PAI-1:Ag.90However, in a
population-based study, anxiety and ﬁbrinogen levels
showed a direct relation controlling for covariates.91
Additional negative affect states being associated with an
increased CVD risk9 have also been associated with a pro-
thrombotic state. For instance, early bereavement has been
associated with increased levels of platelet-granulocyte ag-
gregates, VWF:Ag and FVIII:C, but not ﬁbrinogen, PAI-1:Ag
and t-PA:Ag levels,92 whereas exhaustion has been related to
increased levels of ﬁbrinogen93 and PAI-1 activity.94
Positive Effects and Related Constructs
Positive psychological states might attenuate hypercoagula-
bility so to buffer harmful hemostatic effects of negative effect
states. However, studies on associations of positive effects
and related constructs with hemostatic measures are still
sparse. Dispositional optimism was associated with lowered
ﬁbrinogen levels in a multiethnic population-based study.95
Similarly, in healthy subjects, increases in uplift intensity over
the past month predicted lower levels of PAI-1:Ag levels,
whereas increase in distress related to hassle severity pre-
dicted elevated levels of D-Dimer.96 In women, but not in
men, aged 50 years and older, greater enjoyment of life was
associated with lower ﬁbrinogen levels after controlling for a
range of health characteristics, including depressed mood.97
Underlying Physiological Mechanisms with Chronic
Stress
Activation of the hypothalamic–pituitary–adrenal axis and
decreased parasympathetic activity (i.e., vagal withdrawal)
might bemore important processes underlying hypercoagula-
bility associated with chronic stress compared with acute
stress.5,19 Factory workers showed associations of overnight
urinary excretion of cortisol and catecholamineswithmorning
plasma levels of PAI-1 antigen, ﬁbrinogen, and D-dimer.98
Plasma cortisol levels were also directly correlatedwith ﬁbrin-
ogen andVWF:Ag levels inwomenwith stable CHD99 andwith
ﬁbrinogen in middle-aged men and women.100 Lower high
frequency heart rate variability (HF-HRV; indicating reduced
vagal function) was associated with increased levels of PAI-1:
Ag in healthy individuals101 andwith ﬁbrinogen and activated
FVII in women with stable CHD,102 controlling for a range of
covariates. The association of increased circulating PAI-1 levels
with autonomic dysfunction in humans is supported by stud-
ies in rodents showing increasedgene expression of PAI-1 after
several weeks of unpredictable chronic mild stress,103 follow-
ing restraint stress,104 and after epinephrine and isoprenalin
injection.105 In factory workers, night-time HF-HRV was in-
versely related to plasma ﬁbrinogen levels, with a stronger
relationship for women than men.106 Vagal withdrawal in
chronic stress might mediate hypercoagulability in part via
systemic low-grade inﬂammation. Cross-talk between inﬂam-
mation and hemostasis plays a key role in atherosclerosis
progression,2 and low-grade inﬂammation (e.g., increased
circulating levels of IL-6 andC-reactive protein) is an important
mechanism linking chronic psychosocial stress to atheroscle-
rosis.107 In healthy men and women, there was a direct
relation between plasma levels of IL-6 and sTF if HF-HRV
was low, but not if HF-HRV was high.108
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Results from Intervention Studies
The few randomized placebo-controlled trials testing whether
cardiovascular medications and antidepressants reduce the
prothrombotic state associated with acute and chronic stress
are shown in ►Table 2. Even fewer in number are behavioral
intervention studies targeting prothrombotic measures. Com-
paredwith placebo, the stress response of someprothrombotic
Table 2 Intervention studies examining the relationship between stress and hemostasis
Study population Intervention Outcome
Significant Nonsignificant
56 healthy men and women
undergoing the TSST107
5-d RCT: aspirin 100 mg and/
or 80 mg propranolol daily
versus placebo
Stress response of VWF:Ag #
with aspirin, propranolol, or
aspirin þ propranolol
Stress response of ﬁbrinogen,
FVII:C, FXII:C, D-dimer
54 healthy men and women
undergoing the TSST108
5-d RCT: aspirin 100 mg and/
or 80 mg propranolol daily
versus placebo
Stress response of FVIII:C #
with aspirin þ propranolol
Stress response of FVIII:C with
aspirin
9 men and women with
essential hypertension
undergoing mental
arithmetic109
12-wk RCT: benidipine
2–4 mg daily versus placebo
Stress-induced platelet
activation # (ADP-induced
aggregation, βTG)
Serotonin-induced platelet
aggregation
13 men and women with
essential hypertension
undergoing mental
arithmetic and Stroop110
4-wk RCT: verapamil
240–480 mg daily versus
placebo
Stress response of ADP-in-
duced platelet aggregation #
Stress response of VWF:Ag,
t-PA:Ag,
PAI-1:Ag
45 healthy men undergoing
the TSST111
RCT: single dose of 3 mg
melatonin versus placebo
Stress response of D-dimer # Stress responses of
ﬁbrinogen, FVII:C, FVIII:C
16 men and women with
essential hypertension
undergoing the Stroop112
6-wk RCT: ramipril 5 mg daily
versus placebo
Stress responses of TAT,
ﬁbrinogen, activated FVII
21 men with
hypercholesteremia
undergoing the Stroop113
10–12-wk RCT: simvastatin
20 mg daily versus placebo
Stress responses of platelet
aggregation, βTG
21 men with
hypercholesteremia
undergoing the Stroop114
10–12-wk RCT: gemﬁbrozil
600 mg twice daily versus
placebo
Stress response of platelet
aggregation "
Stress response of βTG
64 postacute coronary
syndrome patients115
24-wk RCT: sertraline
50–200 mg daily versus
placebo
βTG #, sP-sel # Platelet factor 4
57 patients with stable CHD
and current major
depression116
12-wk RCT: citalopram
20–40 mg daily versus
placebo
βTG, sP-sel
108 depressed men and
women, 45 controls117
6-mo outpatient
psychotherapy and/or
antidepressants
CD62p and CD63 positive
platelets #,
CD63 exposure on platelets
after ADP activation #,
large platelet microparticles #
CD62p exposure to
ADP-stimulation, platelet-
leukocyte aggregates
12 men and women with a
severe anxiety disorder and
depression118
8-wk inpatient psychotherapy
with or without psychotropic
medication
FVII:C #
PAI-1:Ag #
VWF:Ag
159 women with stable
CHD119
1-y cognitive behavioral
stress management
(20 2-h sessions) versus
usual care
Fibrinogen, VWF:Ag, PAI-1:
Act, t-PA:Act, t-PA:Ag, t-PA/
PAI-1 complex
18 healthy individuals120 30-min comedy movie
provoking laughter
sP-sel # Fibrinogen
VWF:Ag
Abbreviations: Act, activity; ADP, adenosine diphosphate; Ag, antigen level; βTG, β-thromboglobulin; CHD, coronary heart disease; d, day; FVII:C,
clotting factor VII activity; h, hour; PAI, plasminogen activator inhibitor; RCT, randomized controlled trial; sP-sel, soluble P-selectin; t-PA, tissue-type
plasminogen activator; TAT, thrombin–antithrombin complex; TSST, Trier Social Stress Test; VWF, von Willebrand factor; wk, week(s); y, year(s).
Note: Quantitative changes (#, decreased level; ", increased level).
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measures was mitigated by aspirin,109,110 propranolol,109,110
calcium antagonists,111,112 andmelatonin.113 Conversely, angio-
tensin converting enzyme inhibitor114 and statin115 administra-
tion were both ineffective and ﬁbrate therapy even increased
platelet activation during acute stress.116 However, these ﬁnd-
ings are limited by small sample sizes andheterogeneityof study
populations. Selective serotonin reuptake inhibitors signiﬁcantly
reduced platelet activation in CHD patients in two sudies,117,118
but the decrease in βTG levels was similar to that achieved by
placebo in one of these studies.118
In- andoutpatient psychiatric treatment (psychotherapyand/
or psychotropic medication) for patients with anxiety and/or
depressive disorders resulted in a decrease of some platelet
activation markers119 and of VWF:Ag and FVII:C.120 Moreover,
reductions in depressive symptoms and platelet activationwere
signiﬁcantly correlated with each other after 6 months of
outpatient psychiatric therapy for depression.119 In contrast,
cognitive behavioral stressmanagement had no effect on several
hemostasis measures in CHD patients when compared with
usual care after 1 year.121 The systematic provocation of laughter
might also beneﬁt low-grade hypercoagulability.122
Conclusions
A truly physiological prothrombotic stress response is part of
ﬁght-or-ﬂight response, but can be excessive in vulnerable
individuals under acute stress and become chronic in persons
unable to cope with ongoing life demands. Plausible neuro-
biological, neuroendocrine, and autonomic processes have
been identiﬁed to partially explain how stress affects hemo-
stasis. This knowledge underscores the notion that stress should
be considered an important preanalytical confound of coagula-
tion tests123 and a reason for ﬂuctuations in the international
normalized ratio in patients under OAC therapy.85 However,
clinical implications likely reach much further. Given that
hemostasis is important in atherothrombotic disease and
VTE, a prothrombotic state seems a conceivable mechanism
linking stress to thrombotic manifestations. To support this
assumption, prospective studies are needed to demonstrate
the predictive value of acute and chronic prothrombotic stress
responses for incident and recurrent thrombotic events in
healthy individuals and patients with CHD and VTE. Some
small studies suggest that medications and perhaps behavior-
al interventions have the potential to attenuate the prothrom-
botic stress response.109–113,117–120 To potentially prevent
emotional triggering of atherothrombotic events, stress man-
agement, relaxation, emotion regulation, and even medica-
tion in an effort to sever the link between stress and
pathophysiological consequences have been proposed.124
More controlled studies are warranted to investigate
whether behavioral and/or medication interventions reduce
stress-related hypercoagulability and subsequent thrombotic
risk.
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